In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL)
Ilaria Iacobucci(St. Jude Children's Research Hospital), Giovanni Martinelli(University of Bologna), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Maria Chiara Abbenante(University of Bologna), Emanuela Ottaviani(University of Bologna), Annalisa Lonetti(University of Bologna), Domenico Russo(University of Brescia), Michele Baccarani(University of Bologna), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Pier Giuseppe Pelicci(Office of Technology Transfer), Federica Cattina(University of Brescia), Viviana Guadagnuolo(University of Bologna), Maria Vittoria Verga Falzacappa(University of Trieste), Enrico Derenzini(University of Milan), Claudia Venturi(University of Bologna), Anna Ferrari(University of Bologna)
Cited by 3
Related Papers
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
|Nature reviews. Cancer|2006|2.2k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction
|Cell|1992|1.3k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k